{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:39:17Z","timestamp":1789763957423,"version":"4.0.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.neurot.2024.e00437","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T08:54:29Z","timestamp":1725526469000},"page":"e00437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy"],"prefix":"10.1016","volume":"21","author":[{"given":"Megan A.","family":"Waldrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00437_bib1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/archneur.1971.00490030102014","article-title":"Two early infantile hereditary cases of progressive muscular atrophy simulating dystrophy, but on a neural basis. 1891","volume":"25","author":"Werdnig","year":"1971","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/345823a0","article-title":"Genetic homogeneity between acute and chronic forms of spinal muscular atrophy","volume":"345","author":"Gilliam","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2024.e00437_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01668496","article-title":"Ueber chronische spinale Muskelatrophie im Kindesalter, auf famili\u00e4rer Basis","volume":"3","author":"Hoffman","year":"1893","journal-title":"Dtsch Z f\u00fcr Nervenheilkd"},{"key":"10.1016\/j.neurot.2024.e00437_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0140-6736(90)91803-I","article-title":"Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators","volume":"336","author":"Melki","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2024.e00437_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2024.e00437_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.neurot.2024.e00437_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pediatrneurol.2024.04.015","article-title":"Epidemiology of spinal muscular atrophy based on the results of a large-scale pilot project on 202,908 newborns","volume":"156","author":"Efimova","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib8","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/acn3.52018","article-title":"Early spinal muscular atrophy treatment following newborn screening: a 20-month review of the first Italian regional experience","volume":"11","author":"Gagliardi","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2024.1911","article-title":"Newborn screening and birth prevalence for spinal muscular atrophy in the US","author":"Belter","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.neurot.2024.e00437_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/cjn.2024.1","article-title":"A\u00a0study on the incidence and prevalence of 5q spinal muscular atrophy in Canada using multiple data sources","author":"Price","year":"2024","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.neurot.2024.e00437_bib11","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00437_bib12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00437_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158289","article-title":"Deep molecular characterization of milder spinal muscular atrophy patients carrying the c.859G>C variant in SMN2","volume":"23","author":"Blasco-Perez","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2024.e00437_bib14","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/hmg\/ddx166","article-title":"A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy","volume":"26","author":"Wu","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2024.e00437_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CND.0b013e318190310f","article-title":"Survival probabilities of patients with childhood spinal muscle atrophy","volume":"10","author":"Mannaa","year":"2009","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.neurot.2024.e00437_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0960-8966(94)90090-6","article-title":"The natural history of type I (severe) spinal muscular atrophy","volume":"4","author":"Thomas","year":"1994","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00437_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0887-8994(93)90082-N","article-title":"Prospective study of spinal muscular atrophy before age 6 years. DCN\/SMA Group","volume":"9","author":"Iannaccone","year":"1993","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1440-1754.2003.00266.x","article-title":"Pulmonary function and scoliosis in children with spinal muscular atrophy types II and III","volume":"39","author":"Chng","year":"2003","journal-title":"J\u00a0Paediatr Child Health"},{"key":"10.1016\/j.neurot.2024.e00437_bib19","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00437_bib20","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00437_bib21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201004","article-title":"Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study","volume":"13","author":"Chabanon","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2024.e00437_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0960-8966(97)00113-2","article-title":"Segmental distribution of muscle weakness in SMA III: implications for deterioration in muscle strength with time","volume":"7","author":"Deymeer","year":"1997","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00437_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"The neurobiology of childhood spinal muscular atrophy","volume":"3","author":"Crawford","year":"1996","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2024.e00437_bib25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical variability in spinal muscular atrophy type III","volume":"88","author":"Coratti","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/brain\/101.4.591","article-title":"A\u00a0clinical and genetic study of spinal muscular atrophy of adult onset: the autosomal recessive form as a discrete disease entity","volume":"101","author":"Pearn","year":"1978","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2024.e00437_bib27","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(95)92881-2","article-title":"SMN gene deletions in adult-onset spinal muscular atrophy","volume":"346","author":"Clermont","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2024.e00437_bib28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(95)91507-9","article-title":"Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy","volume":"346","author":"Brahe","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2024.e00437_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1090-3798(99)80012-9","article-title":"Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype","volume":"3","author":"Dubowitz","year":"1999","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib30","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.neurot.2024.e00437_bib31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience","volume":"31","author":"Hache","year":"2016","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib32","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00437_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00437_bib34","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00437_bib35","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00437_bib37","unstructured":"New data at cure SMA highlight potential benefit of SPINRAZA\u00ae (nusinersen) in infants and toddlers with unmet clinical needs after gene therapy."},{"key":"10.1016\/j.neurot.2024.e00437_bib38","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2024.e00437_bib39","article-title":"Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib40","article-title":"Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib41","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","article-title":"Nusinersen treatment in adults with spinal muscular atrophy","volume":"11","author":"Duong","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.neurot.2024.e00437_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib43","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/acn3.51562","article-title":"Scientific rationale for a higher dose of nusinersen","volume":"9","author":"Finkel","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib44","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00437_bib45","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib46","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00437_bib47","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2024.e00437_bib48","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib50","unstructured":"Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA."},{"key":"10.1016\/j.neurot.2024.e00437_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ph17030394","article-title":"Real-world safety data of the orphan drug onasemnogene abeparvovec (Zolgensma((R))) for the SMA rare disease: a pharmacovigilance study based on the ema adverse event reporting system","volume":"17","author":"Ruggiero","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neurot.2024.e00437_bib52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.neurot.2024.e00437_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2022.05.001","article-title":"Safety of onasemnogene abeparvovec for patients with spinal muscular atrophy 8.5 kg or heavier in a global managed access program","volume":"132","author":"Chand","year":"2022","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib54","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.ymthe.2023.08.013","article-title":"Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec","volume":"31","author":"Retson","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurot.2024.e00437_bib55","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"Van Alstyne","year":"2021","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurot.2024.e00437_bib56","unstructured":"AVXS-101 IT Update. [cited 04.14.2023]; Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-avxs-101-intrathecal-study-update."},{"issue":"3","key":"10.1016\/j.neurot.2024.e00437_bib57","first-page":"389","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.neurot.2024.e00437_bib58","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.neurot.2024.e00437_bib59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study","volume":"12","author":"Chiriboga","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2024.e00437_bib60","first-page":"2531","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib61","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-Treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00437_bib62","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/ene.15499","article-title":"Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment","volume":"30","author":"Mercuri","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib64","unstructured":"European Commission approves Roche's Evrysdi for babies under two months old with spinal muscular atrophy (SMA)."},{"key":"10.1016\/j.neurot.2024.e00437_bib65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.omtm.2018.01.007","article-title":"Plastin 3 promotes motor neuron axonal growth and extends survival in a mouse model of spinal muscular atrophy","volume":"9","author":"Alrafiah","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00437_bib66","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/acn3.51560","article-title":"An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy","volume":"9","author":"Kwon","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib67","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41436-020-0824-3","article-title":"Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy","volume":"22","author":"Kay","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.neurot.2024.e00437_bib68","doi-asserted-by":"crossref","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn screening for spinal muscular atrophy in New York state: clinical outcomes from the first 3 years","volume":"99","author":"Lee","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00437_bib69","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.neurot.2024.e00437_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2023.11.010","article-title":"Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio","volume":"34","author":"Waldrop","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00437_bib71","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/cer-2021-0216","article-title":"How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison","volume":"11","author":"Ribero","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.neurot.2024.e00437_bib72","article-title":"Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2024.e00437_bib73","article-title":"A\u00a0versatile toolkit for overcoming AAV immunity","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2024.e00437_bib74","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","volume":"21","author":"Day","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.neurot.2024.e00437_bib75","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.neurot.2024.e00437_bib76","first-page":"145","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.neurot.2024.e00437_bib77","first-page":"97","article-title":"Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.neurot.2024.e00437_bib78","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0883073820928784","article-title":"Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec","volume":"35","author":"Matesanz","year":"2020","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib79","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3174\/ajnr.A5596","article-title":"Transforaminal lumbar puncture: an alternative technique in patients with challenging access","volume":"39","author":"Nascene","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.neurot.2024.e00437_bib80","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1212\/WNL.0000000000006006","article-title":"Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy","volume":"91","author":"Veerapandiyan","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2024.e00437_bib81","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00247-018-4240-7","article-title":"Ultrasound-guided cervical puncture for nusinersen administration in adolescents","volume":"49","author":"Ortiz","year":"2019","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.neurot.2024.e00437_bib82","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1159\/000519831","article-title":"Intrathecal administration of nusinersen using the ommaya reservoir in an adult with 5q-related spinal muscular atrophy type 1 and severe spinal deformity","volume":"13","author":"Papaliagkas","year":"2021","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib83","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","article-title":"Nusinersen in type 1 SMA infants, children and young adults: preliminary results on motor function","volume":"28","author":"Pane","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurot.2024.e00437_bib84","first-page":"2649","article-title":"Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment","volume":"271","author":"Brakemeier","year":"2024","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib85","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40120-024-00626-5","article-title":"Male reproduction in spinal muscular atrophy (SMA) and the potential impact of oral survival of motor neuron 2 (SMN2) pre-mRNA splicing modifiers","volume":"13","author":"Bar-Chama","year":"2024","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2024.e00437_bib86","first-page":"1","article-title":"Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling","year":"2020","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.neurot.2024.e00437_bib87","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurot.2024.e00437_bib88","first-page":"111","article-title":"Neurofilament levels in CSF and serum in an adult SMA cohort treated with nusinersen","volume":"9","author":"Rich","year":"2022","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.neurot.2024.e00437_bib89","first-page":"937","article-title":"Identifying biomarkers of spinal muscular atrophy for further development","volume":"10","author":"Glascock","year":"2023","journal-title":"J\u00a0Neuromuscul Dis"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T01:12:06Z","timestamp":1727140326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1878747924001235"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00437","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00437"}}